[Transition from prostacyclin to bosentan in five patients with severe pulmonary hypertension: the switch is possible].
Prostacyclin improves symptoms, exercise tolerance, and survival in patients with pulmonary arterial hypertension. However, the difficulty of administration (whether intravenous, subcutaneous, or by inhalation) often causes side effects that can reduce the patient's quality of life and which may sometimes be serious. Bosentan, an orally active endothelin receptor antagonist, improves functional class and exercise tolerance in these patients. We describe the successful transition from prostacyclin to bosentan in five patients with severe pulmonary arterial hypertension who suffered serious side effects with prostacyclin treatment.
Flox Camacho
Angela
A
Servicio de Cardiología, Unidad de Hipertensión Pulmonar, Insuficiencia Cardiaca y Trasplante Cardiaco, Hospital Universitario 12 de Octubre, Madrid, España. angelaflox@gmail.com
Escribano Subías
Pilar
P
Tello de Meneses
Rocío
R
Delgado Jiménez
Juan
J
Gómez Sánchez
Miguel A
MA
Sáenz de la Calzada
Carlos
C
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D013449:Sulfonamides; D011464:Epoprostenol; D000077300:Bosentan